Drug Profile
Research programme: anticancer therapeutics - University of Pittsburgh
Alternative Names: Anticancer therapeutics research programme - University of PittsburghLatest Information Update: 25 Aug 2006
Price :
$50
*
At a glance
- Originator University of Pittsburgh Cancer Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 25 Aug 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 25 Sep 2002 Preclinical trials in Cancer in USA (unspecified route)